NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Neuraptive Therapeutics

Neuraptive Therapeutics

Private
Chesterbrook, PennsylvaniaHealthcare & Life Scienceshttps://www.neuraptive.com/

Last Round

Series B

Oct 14, 2022

Est. Valuation

$149.5M

Total Funding Raised

$32M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Neuraptive Therapeutics is a biotechnology company that develops novel therapeutics and medical products to improve outcomes for peripheral nerve injuries.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

peripheral nerve repairnerve regenerationsurgical adjunctmedical devicenerve fusionmicrosurgical instrumentsbiotechnologyreconstructive surgerytrauma surgerynerve repair kitneuropathic painnerve graftsurgical techmedtech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Neuraptive Therapeutics Comparables

Compare Neuraptive Therapeutics with similar companies based on industry and business-model similarity.

Neuraptive Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
BioCircuit Technologies
82%
Regenity Biosciences
79%
Axogen Inc
79%

Neuraptive Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BOct 14, 2022
Series ADec 19, 2018
SeedSep 6, 2017

Key People

Founding team and executive leadership

Robert S. Radie

Chairman Of The Board And Chief Executive Officer

Executive Team

Neuraptive Therapeutics Investors

Notable investors and investment history

Neuraptive Therapeutics investors
InvestorRounds
Benjamin Franklin Technology PartnersSeries A
New Rhein Healthcare InvestorsSeries A
Central Texas Angel NetworkSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 18, 2026

    Monthly visitors increased 99% MoM to 1.7K.

  • Apr 16, 2026

    Monthly visitors increased 30% MoM.

Neuraptive Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Neuraptive Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Neuraptive Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersChesterbrook, Pennsylvania
Employee Range13
Year Founded2016
Last FundingOct 14, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.